A Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Intravenous CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus, With a 52-Week Open Label Extension

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 11 Nov 2019

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Difelikefalin (Primary)
Indications Pruritus
Focus Registrational; Therapeutic Use
Acronyms KALM-1
Sponsors Cara Therapeutics

Most Recent Events

11 Nov 2019 Results presented in a Cara Therapeutics Media Release.
08 Nov 2019 According to The Feinstein Institute for Medical Research media release, results from this trial were presented at the American Society of Nephrology 2019 Kidney Week on November 8.
08 Nov 2019 Results assessing itch intensity and improved itch-related quality of life were published in the New England Journal of Medicine

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Welcome to AdisInsight